Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
18.84 HKD | +4.67% | +4.78% | +35.54% |
05-24 | Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation | MT |
05-24 | Henlius' EU Marketing Application for Denosumab Biosimilar Accepted and Validated by Regulator | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+35.54% | 1.31B | |
-2.29% | 90.02B | |
-1.18% | 39.15B | |
-15.83% | 31.71B | |
+62.86% | 26.47B | |
-21.68% | 14.34B | |
-8.73% | 12.89B | |
-15.05% | 11.18B | |
-45.69% | 10.97B | |
+4.94% | 8.94B |
- Stock Market
- Equities
- 2696 Stock
- News Shanghai Henlius Biotech, Inc.
- Henlius Biotech Gets US FDA Clearance for Phase 3 Trial of Gastric Cancer Combination Therapy